65
Participants
Start Date
September 1, 2020
Primary Completion Date
August 31, 2024
Study Completion Date
September 25, 2024
Ponatinib
Ponatinib treatment will be initiated per usual treatment procedure at 45 mg once daily p.o., which will be gradually decreased to 30 mg and 15 mg according to the predefined criteria based on responsiveness to treatment and AEs in the course of the treatment.
Seoul St. Mary's Hospital, Seoul
Collaborators (1)
Ulsan National Institute of Science and Technology
UNKNOWN
Takeda
INDUSTRY
Dong-Wook Kim
OTHER